<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01556763</url>
  </required_header>
  <id_info>
    <org_study_id>EVP-6124-005</org_study_id>
    <nct_id>NCT01556763</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Randomized Study to Assess the Safety, Tolerability, and Pharmacokinetics of EVP-6124 in Participants With Schizophrenia on Stable Monotherapy With Selected Antipsychotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FORUM Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FORUM Pharmaceuticals Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study in patients with schizophrenia is designed to provide preliminary evidence of the
      safety, tolerability, and pharmacokinetics as well as the effects on cognitive function of 2
      doses of EVP-6124 compared with placebo when given with the patient's usual antipsychotic
      medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study drug will be supplied as capsules and will be orally administered once daily for a
      total of 21 days. Eligible subjects will be admitted to an inpatient study unit on Day -6
      (six days before the first dose of study drug is administered) and will remain confined to
      the inpatient study unit throughout the dosing phase. Safety assessments, PK sampling, and
      cognitive testing will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Serious and Non-serious Adverse Events Spontaneously Reported by Subject and/or Observed by Investigator.</measure>
    <time_frame>Screening (Day -5 for continuous cardiac monitoring) to Day 22</time_frame>
    <description>Safety and tolerability was measured by number of reported adverse events (serious and non-serious) and repeated clinical evaluation of physical examinations, vital signs, 12-lead electrocardiogram (ECG), 24-hour continuous cardiac monitoring, and laboratory tests (hematology/blood chemistry/urinalysis).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EVP-6124 Maximum Plasma Concentration (Cmax), Patients on Aripiprazole</measure>
    <time_frame>Days 1 and 21</time_frame>
    <description>Blood samples for pharmacokinetic (PK) analyses were taken before dosing with EVP-6124 on Days 1 and 21.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EVP-6124 Time to Maximum Concentration (Tmax), Patients on Aripiprazole</measure>
    <time_frame>Days 1 and 21</time_frame>
    <description>Blood samples for PK analyses were taken before dosing with EVP-6124 on Days 1 and 21.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EVP-6124 Area Under the Curve (AUC[0-24 h]), Patients on Aripiprazole</measure>
    <time_frame>Days 1 and 21</time_frame>
    <description>Blood samples for PK analyses were taken before dosing with EVP-6124 on Days 1 and 21.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EVP-6124 Half-life (T[1/2]), Patients on Aripiprazole</measure>
    <time_frame>Days 1 and 21</time_frame>
    <description>Blood samples for PK analyses were taken before dosing with EVP-6124 on Days 1 and 21.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EVP-6124 Maximum Plasma Concentration (Cmax), Patients on Paliperidone/Risperidone</measure>
    <time_frame>Days 1 and 21</time_frame>
    <description>Blood samples for PK analyses were taken before dosing with EVP-6124 on Days 1 and 21.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EVP-6124 Time to Maximum Concentration (Tmax), Patients on Paliperidone/Risperidone</measure>
    <time_frame>Days 1 and 21</time_frame>
    <description>Blood samples for PK analyses were taken before dosing with EVP-6124 on Days 1 and 21.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EVP-6124 Area Under the Curve (AUC[0-24 h]), Patients on Paliperidone/Risperidone</measure>
    <time_frame>Days 1 and 21</time_frame>
    <description>Blood samples for PK analyses were taken before dosing with EVP-6124 on Days 1 and 21.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EVP-6124 Half-life (T[1/2]), Patients on Paliperidone/Risperidone</measure>
    <time_frame>Days 1 and 21</time_frame>
    <description>Blood samples for PK analyses were taken before dosing with EVP-6124 on Days 1 and 21.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>N100 Gating Ratio</measure>
    <time_frame>Days -1 to 20</time_frame>
    <description>N100 auditory evoked potential response (amplitude measured in microvolts) using the sensory gating paradigm. Measured by electroencephalography (EEG) as the amplitude ratio of test stimulus to conditioning stimulus. Plotted on a unitless scale of 0 to 2. Normalization is suggested by a lower value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P50 Amplitude Difference</measure>
    <time_frame>Days -1 to 20</time_frame>
    <description>P50 auditory evoked potential response (amplitude measured in microvolts) using sensory gating paradigm. Measured by EEG as amplitude difference (conditioning stimulus minus test stimulus). Plotted on a scale of -0.2 to 0.8 microvolts. Normalization is suggested by a higher value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMN Summed Amplitude</measure>
    <time_frame>Days -1 to 20</time_frame>
    <description>Mismatch negativity (MMN) auditory evoked potential response (amplitude in microvolts) using orienting paradigm. Measured by EEG and calculated as the voltage difference over 100-200 msec following stimulus onset (rare stimulus minus frequent stimulus). Plotted on a scale of -1.2 to 0.2 microvolts. Normalization is suggested by a more negative value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P300 Peak Amplitude</measure>
    <time_frame>Days -1 to 20</time_frame>
    <description>P300 auditory evoked potential response (amplitude in microvolts) using orienting paradigm. Measured by EEG and calculated as the peak amplitude over 250-500 msec following stimulus onset (rare stimulus minus frequent stimulus). Plotted on a scale of -0.4 to 1.2 microvolts. Normalization is suggested by a more positive value.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <condition>Central Nervous System Diseases</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo was administered as one capsule per day for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EVP-6124 (1.0 mg/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EVP-6124 (0.3 mg/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EVP-6124 (0.3 mg/day)</intervention_name>
    <description>EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.</description>
    <arm_group_label>EVP-6124 (0.3 mg/day)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EVP-6124 (1.0 mg/day)</intervention_name>
    <description>EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.</description>
    <arm_group_label>EVP-6124 (1.0 mg/day)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo was administered as one capsule per day for 21 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antipsychotic therapy</intervention_name>
    <description>Concomitant therapy with antipsychotic medication (aripiprazole [10 to 30 mg/day], olanzapine [10 to 20 mg/day], paliperidone [3 to 12 mg/day], or risperidone [2 to 16 mg/day]), taken at the same time each day as the EVP-6124 dose. Patients must have been taking concomitant therapy for at least 2 weeks at a stable dose to be eligible for the study.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>EVP-6124 (1.0 mg/day)</arm_group_label>
    <arm_group_label>EVP-6124 (0.3 mg/day)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged 18 to 55 years (both inclusive).

          -  Females must be surgically sterile, post-menopausal, or using reliable contraception
             and have negative pregnancy tests at screening and at Day -1.

          -  A clinical diagnosis of schizophrenia or schizoaffective disorder and prescribed a
             stable dose of aripiprazole (10 to 30 mg/day), olanzapine (10 to 20 mg/day),
             paliperidone (3 to 12 mg/day), or risperidone (2 to 16 mg/day) for a minimum of 2
             weeks before initial screening.

          -  In good general health and expected to complete the clinical trial as designed.

          -  Body Mass Index (BMI) of 18 kg/m^2 to 38 kg/m^2 (both inclusive) at screening.

          -  Adequate hearing, vision, and language skills to perform the cognitive testing and
             other procedures specified in the protocol.

          -  Voluntarily provided informed consent and signed an informed consent form (ICF)
             indicating that the purpose of the study was explained, and was willing and able to
             adhere to the study regimen and study procedures described in the ICF, including all
             confinement requirements.

          -  Negative urine drug screen at screening and inpatient observation baseline period (Day
             -6), except for a short-acting benzodiazepine if prescribed for insomnia.

          -  Fluent in English (speaking, writing, and reading).

        Exclusion Criteria:

          -  Female subject who was pregnant or breast-feeding.

          -  Any active clinically significant medical condition within 1 month (30 days) prior to
             screening.

          -  A history of substance (drug) dependence or substance or alcohol abuse within the 12
             months before randomization as defined in the Diagnostic and Statistical Manual of
             Mental Disorders, 4th Edition (DSM-IV).

          -  A score of &gt;5 on any item on the PANSS (Positive and Negative Syndrome Scale) Positive
             subscale at baseline during the inpatient observation period (Day -1).

          -  Any laboratory test abnormalities at screening indicating hepatic or renal
             dysfunction, or any other laboratory test abnormalities deemed by the investigator to
             be clinically significant.

          -  Any hematologic malignancy or solid tumor diagnosed within 3 years prior to study
             entry with the exception of localized skin cancer or carcinoma in situ of the cervix.

          -  Known to have had or was a carrier of HBsAg, HCV antibody, or had a positive result to
             the HIV-1 and/or HIV-2 antibodies.

          -  Uncooperative with or could not complete the study procedures.

          -  Received an investigational drug within 30 days before screening.

          -  Donated blood within 30 days before randomization on Day 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheldon H. Preskorn, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2012</study_first_submitted>
  <study_first_submitted_qc>March 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2012</study_first_posted>
  <results_first_submitted>April 18, 2012</results_first_submitted>
  <results_first_submitted_qc>May 21, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 21, 2012</results_first_posted>
  <last_update_submitted>May 21, 2012</last_update_submitted>
  <last_update_submitted_qc>May 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Schizoaffective</keyword>
  <keyword>CNS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Central Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Matching placebo was administered as one capsule per day for 21 days.</description>
        </group>
        <group group_id="P2">
          <title>EVP-6124 (1.0 mg/Day)</title>
          <description>EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.</description>
        </group>
        <group group_id="P3">
          <title>EVP-6124 (0.3 mg/Day)</title>
          <description>EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Matching placebo was administered as one capsule per day for 21 days.</description>
        </group>
        <group group_id="B2">
          <title>EVP-6124 (1.0 mg/Day)</title>
          <description>EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.</description>
        </group>
        <group group_id="B3">
          <title>EVP-6124 (0.3 mg/Day)</title>
          <description>EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.0" spread="11.6"/>
                    <measurement group_id="B2" value="43.1" spread="11.0"/>
                    <measurement group_id="B3" value="51.4" spread="6.9"/>
                    <measurement group_id="B4" value="45.7" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Serious and Non-serious Adverse Events Spontaneously Reported by Subject and/or Observed by Investigator.</title>
        <description>Safety and tolerability was measured by number of reported adverse events (serious and non-serious) and repeated clinical evaluation of physical examinations, vital signs, 12-lead electrocardiogram (ECG), 24-hour continuous cardiac monitoring, and laboratory tests (hematology/blood chemistry/urinalysis).</description>
        <time_frame>Screening (Day -5 for continuous cardiac monitoring) to Day 22</time_frame>
        <population>All randomized patients who ingested at least one dose of study drug or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo was administered as one capsule per day for 21 days.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 (1.0 mg/Day)</title>
            <description>EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.</description>
          </group>
          <group group_id="O3">
            <title>EVP-6124 (0.3 mg/Day)</title>
            <description>EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious and Non-serious Adverse Events Spontaneously Reported by Subject and/or Observed by Investigator.</title>
          <description>Safety and tolerability was measured by number of reported adverse events (serious and non-serious) and repeated clinical evaluation of physical examinations, vital signs, 12-lead electrocardiogram (ECG), 24-hour continuous cardiac monitoring, and laboratory tests (hematology/blood chemistry/urinalysis).</description>
          <population>All randomized patients who ingested at least one dose of study drug or placebo.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="5" spread="0"/>
                    <measurement group_id="O3" value="5" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Adverse Events Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="0"/>
                    <measurement group_id="O2" value="4" spread="0"/>
                    <measurement group_id="O3" value="3" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>EVP-6124 Maximum Plasma Concentration (Cmax), Patients on Aripiprazole</title>
        <description>Blood samples for pharmacokinetic (PK) analyses were taken before dosing with EVP-6124 on Days 1 and 21.</description>
        <time_frame>Days 1 and 21</time_frame>
        <population>All patients receiving aripiprazole.</population>
        <group_list>
          <group group_id="O1">
            <title>EVP-6124 (1.0 mg/Day)</title>
            <description>EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 (0.3 mg/Day)</title>
            <description>EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>EVP-6124 Maximum Plasma Concentration (Cmax), Patients on Aripiprazole</title>
          <description>Blood samples for pharmacokinetic (PK) analyses were taken before dosing with EVP-6124 on Days 1 and 21.</description>
          <population>All patients receiving aripiprazole.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="581.0" spread="149.8"/>
                    <measurement group_id="O2" value="210.0" spread="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2058.6" spread="393.2"/>
                    <measurement group_id="O2" value="968.3" spread="90.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>EVP-6124 Time to Maximum Concentration (Tmax), Patients on Aripiprazole</title>
        <description>Blood samples for PK analyses were taken before dosing with EVP-6124 on Days 1 and 21.</description>
        <time_frame>Days 1 and 21</time_frame>
        <population>All patients receiving aripiprazole.</population>
        <group_list>
          <group group_id="O1">
            <title>EVP-6124 (1.0 mg/Day)</title>
            <description>EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 (0.3 mg/Day)</title>
            <description>EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>EVP-6124 Time to Maximum Concentration (Tmax), Patients on Aripiprazole</title>
          <description>Blood samples for PK analyses were taken before dosing with EVP-6124 on Days 1 and 21.</description>
          <population>All patients receiving aripiprazole.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="2" upper_limit="8"/>
                    <measurement group_id="O2" value="8.0" lower_limit="6" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="2" upper_limit="8"/>
                    <measurement group_id="O2" value="8.0" lower_limit="1" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>EVP-6124 Area Under the Curve (AUC[0-24 h]), Patients on Aripiprazole</title>
        <description>Blood samples for PK analyses were taken before dosing with EVP-6124 on Days 1 and 21.</description>
        <time_frame>Days 1 and 21</time_frame>
        <population>All patients receiving aripiprazole.</population>
        <group_list>
          <group group_id="O1">
            <title>EVP-6124 (1.0 mg/Day)</title>
            <description>EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 (0.3 mg/Day)</title>
            <description>EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>EVP-6124 Area Under the Curve (AUC[0-24 h]), Patients on Aripiprazole</title>
          <description>Blood samples for PK analyses were taken before dosing with EVP-6124 on Days 1 and 21.</description>
          <population>All patients receiving aripiprazole.</population>
          <units>pg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10,966" spread="2831"/>
                    <measurement group_id="O2" value="3838" spread="1044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42,042" spread="9623"/>
                    <measurement group_id="O2" value="20,560" spread="2699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>EVP-6124 Half-life (T[1/2]), Patients on Aripiprazole</title>
        <description>Blood samples for PK analyses were taken before dosing with EVP-6124 on Days 1 and 21.</description>
        <time_frame>Days 1 and 21</time_frame>
        <population>Patients receiving aripiprazole for whom blood samples were available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>EVP-6124 (1.0 mg/Day)</title>
            <description>EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 (0.3 mg/Day)</title>
            <description>EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>EVP-6124 Half-life (T[1/2]), Patients on Aripiprazole</title>
          <description>Blood samples for PK analyses were taken before dosing with EVP-6124 on Days 1 and 21.</description>
          <population>Patients receiving aripiprazole for whom blood samples were available for analysis.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0">Data for only one patient were available.</measurement>
                    <measurement group_id="O2" value="43.1">Data for only one patient were available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The patient withdrew consent after receiving study drug for 3 days.</measurement>
                    <measurement group_id="O2" value="116.6">Data for only one patient were available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>EVP-6124 Maximum Plasma Concentration (Cmax), Patients on Paliperidone/Risperidone</title>
        <description>Blood samples for PK analyses were taken before dosing with EVP-6124 on Days 1 and 21.</description>
        <time_frame>Days 1 and 21</time_frame>
        <population>All patients receiving paliperidone/risperidone.</population>
        <group_list>
          <group group_id="O1">
            <title>EVP-6124 (1.0 mg/Day)</title>
            <description>EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 (0.3 mg/Day)</title>
            <description>EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>EVP-6124 Maximum Plasma Concentration (Cmax), Patients on Paliperidone/Risperidone</title>
          <description>Blood samples for PK analyses were taken before dosing with EVP-6124 on Days 1 and 21.</description>
          <population>All patients receiving paliperidone/risperidone.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315.0">Data for only one patient were available.</measurement>
                    <measurement group_id="O2" value="165.0" spread="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1510.0">Data for only one patient were available.</measurement>
                    <measurement group_id="O2" value="545.4" spread="130.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>EVP-6124 Time to Maximum Concentration (Tmax), Patients on Paliperidone/Risperidone</title>
        <description>Blood samples for PK analyses were taken before dosing with EVP-6124 on Days 1 and 21.</description>
        <time_frame>Days 1 and 21</time_frame>
        <population>All patients receiving paliperidone/risperidone.</population>
        <group_list>
          <group group_id="O1">
            <title>EVP-6124 (1.0 mg/Day)</title>
            <description>EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 (0.3 mg/Day)</title>
            <description>EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>EVP-6124 Time to Maximum Concentration (Tmax), Patients on Paliperidone/Risperidone</title>
          <description>Blood samples for PK analyses were taken before dosing with EVP-6124 on Days 1 and 21.</description>
          <population>All patients receiving paliperidone/risperidone.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0">Data for only one patient were available.</measurement>
                    <measurement group_id="O2" value="8.0" lower_limit="6" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0">Data for only one patient were available.</measurement>
                    <measurement group_id="O2" value="8.0" lower_limit="8" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>EVP-6124 Area Under the Curve (AUC[0-24 h]), Patients on Paliperidone/Risperidone</title>
        <description>Blood samples for PK analyses were taken before dosing with EVP-6124 on Days 1 and 21.</description>
        <time_frame>Days 1 and 21</time_frame>
        <population>All patients receiving paliperidone/risperidone.</population>
        <group_list>
          <group group_id="O1">
            <title>EVP-6124 (1.0 mg/Day)</title>
            <description>EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 (0.3 mg/Day)</title>
            <description>EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>EVP-6124 Area Under the Curve (AUC[0-24 h]), Patients on Paliperidone/Risperidone</title>
          <description>Blood samples for PK analyses were taken before dosing with EVP-6124 on Days 1 and 21.</description>
          <population>All patients receiving paliperidone/risperidone.</population>
          <units>pg*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6359">Data for only one patient were available.</measurement>
                    <measurement group_id="O2" value="3110" spread="852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33,042">Data for only one patient were available.</measurement>
                    <measurement group_id="O2" value="11,888" spread="3095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>EVP-6124 Half-life (T[1/2]), Patients on Paliperidone/Risperidone</title>
        <description>Blood samples for PK analyses were taken before dosing with EVP-6124 on Days 1 and 21.</description>
        <time_frame>Days 1 and 21</time_frame>
        <population>Patients receiving paliperidone/risperidone for whom blood samples were available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>EVP-6124 (1.0 mg/Day)</title>
            <description>EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 (0.3 mg/Day)</title>
            <description>EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>EVP-6124 Half-life (T[1/2]), Patients on Paliperidone/Risperidone</title>
          <description>Blood samples for PK analyses were taken before dosing with EVP-6124 on Days 1 and 21.</description>
          <population>Patients receiving paliperidone/risperidone for whom blood samples were available for analysis.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.0">Data for only one patient were available.</measurement>
                    <measurement group_id="O2" value="45.8" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Sample not analyzed.</measurement>
                    <measurement group_id="O2" value="78.1" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>N100 Gating Ratio</title>
        <description>N100 auditory evoked potential response (amplitude measured in microvolts) using the sensory gating paradigm. Measured by electroencephalography (EEG) as the amplitude ratio of test stimulus to conditioning stimulus. Plotted on a unitless scale of 0 to 2. Normalization is suggested by a lower value.</description>
        <time_frame>Days -1 to 20</time_frame>
        <population>Subjects providing valid and measurable N100 responses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo was administered as one capsule per day for 21 days.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 (1.0 mg/Day)</title>
            <description>EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.</description>
          </group>
          <group group_id="O3">
            <title>EVP-6124 (0.3 mg/Day)</title>
            <description>EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>N100 Gating Ratio</title>
          <description>N100 auditory evoked potential response (amplitude measured in microvolts) using the sensory gating paradigm. Measured by electroencephalography (EEG) as the amplitude ratio of test stimulus to conditioning stimulus. Plotted on a unitless scale of 0 to 2. Normalization is suggested by a lower value.</description>
          <population>Subjects providing valid and measurable N100 responses.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.648" spread="0.29"/>
                    <measurement group_id="O2" value="0.801" spread="0.19"/>
                    <measurement group_id="O3" value="0.951" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline value was the covariate and all values obtained during the treatment period were averaged together. This value was adjusted by regression against the baseline and estimation of a new value as if all subjects possessed the same baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.10</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>P50 Amplitude Difference</title>
        <description>P50 auditory evoked potential response (amplitude measured in microvolts) using sensory gating paradigm. Measured by EEG as amplitude difference (conditioning stimulus minus test stimulus). Plotted on a scale of -0.2 to 0.8 microvolts. Normalization is suggested by a higher value.</description>
        <time_frame>Days -1 to 20</time_frame>
        <population>Subjects providing valid and measurable P50 responses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo was administered as one capsule per day for 21 days.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 (1.0 mg/Day)</title>
            <description>EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.</description>
          </group>
          <group group_id="O3">
            <title>EVP-6124 (0.3 mg/Day)</title>
            <description>EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>P50 Amplitude Difference</title>
          <description>P50 auditory evoked potential response (amplitude measured in microvolts) using sensory gating paradigm. Measured by EEG as amplitude difference (conditioning stimulus minus test stimulus). Plotted on a scale of -0.2 to 0.8 microvolts. Normalization is suggested by a higher value.</description>
          <population>Subjects providing valid and measurable P50 responses.</population>
          <units>microvolts</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.38"/>
                    <measurement group_id="O2" value="0.67" spread="0.21"/>
                    <measurement group_id="O3" value="-0.06" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline value was the covariate and all values obtained during the treatment period were averaged together. This value was adjusted by regression against the baseline and estimation of a new value as if all subjects possessed the same baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.07</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MMN Summed Amplitude</title>
        <description>Mismatch negativity (MMN) auditory evoked potential response (amplitude in microvolts) using orienting paradigm. Measured by EEG and calculated as the voltage difference over 100-200 msec following stimulus onset (rare stimulus minus frequent stimulus). Plotted on a scale of -1.2 to 0.2 microvolts. Normalization is suggested by a more negative value.</description>
        <time_frame>Days -1 to 20</time_frame>
        <population>Subjects providing valid and measurable MMN responses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo was administered as one capsule per day for 21 days.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 (1.0 mg/Day)</title>
            <description>EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.</description>
          </group>
          <group group_id="O3">
            <title>EVP-6124 (0.3 mg/Day)</title>
            <description>EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>MMN Summed Amplitude</title>
          <description>Mismatch negativity (MMN) auditory evoked potential response (amplitude in microvolts) using orienting paradigm. Measured by EEG and calculated as the voltage difference over 100-200 msec following stimulus onset (rare stimulus minus frequent stimulus). Plotted on a scale of -1.2 to 0.2 microvolts. Normalization is suggested by a more negative value.</description>
          <population>Subjects providing valid and measurable MMN responses.</population>
          <units>microvolts</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.33"/>
                    <measurement group_id="O2" value="-1.15" spread="0.24"/>
                    <measurement group_id="O3" value="-0.61" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline value was the covariate and all values obtained during the treatment period were averaged together. This value was adjusted by regression against the baseline and estimation of a new value as if all subjects possessed the same baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.02</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>P300 Peak Amplitude</title>
        <description>P300 auditory evoked potential response (amplitude in microvolts) using orienting paradigm. Measured by EEG and calculated as the peak amplitude over 250-500 msec following stimulus onset (rare stimulus minus frequent stimulus). Plotted on a scale of -0.4 to 1.2 microvolts. Normalization is suggested by a more positive value.</description>
        <time_frame>Days -1 to 20</time_frame>
        <population>Subjects providing valid and measurable P300 responses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching placebo was administered as one capsule per day for 21 days.</description>
          </group>
          <group group_id="O2">
            <title>EVP-6124 (1.0 mg/Day)</title>
            <description>EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.</description>
          </group>
          <group group_id="O3">
            <title>EVP-6124 (0.3 mg/Day)</title>
            <description>EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>P300 Peak Amplitude</title>
          <description>P300 auditory evoked potential response (amplitude in microvolts) using orienting paradigm. Measured by EEG and calculated as the peak amplitude over 250-500 msec following stimulus onset (rare stimulus minus frequent stimulus). Plotted on a scale of -0.4 to 1.2 microvolts. Normalization is suggested by a more positive value.</description>
          <population>Subjects providing valid and measurable P300 responses.</population>
          <units>microvolts</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.31"/>
                    <measurement group_id="O2" value="1.08" spread="0.22"/>
                    <measurement group_id="O3" value="0.78" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Baseline value was the covariate and all values obtained during the treatment period were averaged together. This value was adjusted by regression against the baseline and estimation of a new value as if all subjects possessed the same baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.008</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Screening to Day 22</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matching placebo was administered as one capsule per day for 21 days.</description>
        </group>
        <group group_id="E2">
          <title>EVP-6124 (1.0 mg/Day)</title>
          <description>EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.</description>
        </group>
        <group group_id="E3">
          <title>EVP-6124 (0.3 mg/Day)</title>
          <description>EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric symptom</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tinea cruris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric symptom</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin erosion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maria Gawryl, Ph.D., Vice President, Regulatory Affairs &amp; Drug Development</name_or_title>
      <organization>EnVivo Pharmaceuticals, Inc.</organization>
      <phone>617-225-4264</phone>
      <email>mgawryl@envivopharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

